Elicio Therapeutics, Inc.
ELTXNASDAQHealthcare● Active
$13.55
+$0.29(+2.19%)
Market Cap$258616384
P/E Ratio—
52W High$14.93
52W Low$7.37
Elicio Therapeutics, Inc. (ELTX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ELTX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 11, 2026EPS Actual
-$0.65
Est. -$0.49 · -32.6%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 11, 2026
After Market Close
▼ Miss EPS
ELTX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.46 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 11, 2026 | -$0.49 | -$0.65 | -32.6% | — | — | — |
| ▼ Q1 FY2026 | Mar 12, 2026 | -$0.47 | -$0.49 | -4.3% | — | — | — |
| ▲ Q4 FY2025 | Nov 13, 2025 | -$0.62 | -$0.60 | +3.2% | — | — | — |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$0.69 | -$0.66 | +4.3% | — | — | — |
| ▼ Q2 FY2025 | May 13, 2025 | -$0.67 | -$0.87 | -29.9% | — | — | — |
| ▼ Q1 FY2025 | Mar 31, 2025 | -$0.94 | -$1.02 | -8.5% | $0.00B | — | — |
| ▼ Q4 FY2024 | Nov 13, 2024 | -$0.81 | -$1.39 | -71.6% | — | — | — |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.46
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 11, 2026Miss
EPS Actual
-$0.65
EPS Est.
-$0.49
EPS Surpr.
-32.6%
Revenue
—
Q1 FY2026
Mar 12, 2026Miss
EPS Actual
-$0.49
EPS Est.
-$0.47
EPS Surpr.
-4.3%
Revenue
—
Q4 FY2025
Nov 13, 2025Beat
EPS Actual
-$0.60
EPS Est.
-$0.62
EPS Surpr.
+3.2%
Revenue
—
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
-$0.66
EPS Est.
-$0.69
EPS Surpr.
+4.3%
Revenue
—
Q2 FY2025
May 13, 2025Miss
EPS Actual
-$0.87
EPS Est.
-$0.67
EPS Surpr.
-29.9%
Revenue
—
Q1 FY2025
Mar 31, 2025Miss
EPS Actual
-$1.02
EPS Est.
-$0.94
EPS Surpr.
-8.5%
Revenue
$0.00B
Q4 FY2024
Nov 13, 2024Miss
EPS Actual
-$1.39
EPS Est.
-$0.81
EPS Surpr.
-71.6%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.43 | $-0.43 | $-0.43 | 1 |
| Q3 FY2026 | $-0.41 | $-0.41 | $-0.41 | 1 |
| Q2 FY2026 | $-0.49 | $-0.49 | $-0.49 | 1 |
| Q1 FY2026 | $-0.47 | $-0.47 | $-0.47 | 1 |
| Q4 FY2025 | $-0.45 | $-0.45 | $-0.45 | 1 |
| Q3 FY2025 | $-0.48 | $-0.48 | $-0.48 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 11, 2026 | -32.6% | $9.91 | $11.61 | +17.15% |
| ▼ Q1 FY2026 | Mar 12, 2026 | -4.3% | $11.79 | $10.90 | -7.55% |
| ▲ Q4 FY2025 | Nov 13, 2025 | +3.2% | $9.19 | $9.11 | -0.87% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +4.3% | $9.37 | $9.07 | -3.20% |
| ▼ Q2 FY2025 | May 13, 2025 | -29.9% | $5.52 | $5.71 | +3.44% |
| ▼ Q1 FY2025 | Mar 31, 2025 | -8.5% | $7.79 | $6.16 | -20.92% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -71.6% | $5.01 | $5.20 | +3.79% |
| ▲ Q3 FY2024 | Aug 13, 2024 | +33.3% | $4.32 | $4.53 | +4.86% |
Q2 FY2026+17.15%
Report Date
May 11, 2026
EPS Beat/Miss
-32.6%
Price Before
$9.91
Price After
$11.61
Q1 FY2026-7.55%
Report Date
Mar 12, 2026
EPS Beat/Miss
-4.3%
Price Before
$11.79
Price After
$10.90
Q4 FY2025-0.87%
Report Date
Nov 13, 2025
EPS Beat/Miss
+3.2%
Price Before
$9.19
Price After
$9.11
Q3 FY2025-3.20%
Report Date
Aug 7, 2025
EPS Beat/Miss
+4.3%
Price Before
$9.37
Price After
$9.07
Q2 FY2025+3.44%
Report Date
May 13, 2025
EPS Beat/Miss
-29.9%
Price Before
$5.52
Price After
$5.71
Q1 FY2025-20.92%
Report Date
Mar 31, 2025
EPS Beat/Miss
-8.5%
Price Before
$7.79
Price After
$6.16
Q4 FY2024+3.79%
Report Date
Nov 13, 2024
EPS Beat/Miss
-71.6%
Price Before
$5.01
Price After
$5.20
Q3 FY2024+4.86%
Report Date
Aug 13, 2024
EPS Beat/Miss
+33.3%
Price Before
$4.32
Price After
$4.53
Avg Beat Reaction+0.26%
Avg Miss Reaction-0.82%
Beat Rate3 / 8 quarters
Largest Move-20.92% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ELTX ends December
Elicio Therapeutics, Inc. (ELTX) most recently reported earnings on May 11, 2026 for Q2 FY2026, posting EPS of $-0.65 — missing the analyst consensus of $-0.49 by -32.6%. The next ELTX earnings date is expected around September 1, 2026.
Each quarter, investors track ELTX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ELTX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ELTX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ELTX earnings · 5 questionsElicio Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. ELTX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ELTX historically reports after market close (AMC).
ELTX earnings datewhen is ELTX earningsELTX next earnings datewhen does ELTX report earningsELTX earnings calendar
▸ Source: FMP · Elicio Therapeutics, Inc. SEC filings · US GAAP · Elicio Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026